超10亿，江西国资接手这家药企

Core Viewpoint - The acquisition of Tai Long Pharmaceutical by Jiang Pharmaceutical Holdings is part of a broader trend of state-owned enterprises entering the pharmaceutical industry for strategic collaboration and resource acquisition [1][9]. Group 1: Acquisition Details - Jiang Pharmaceutical Holdings will become the new controlling shareholder of Tai Long Pharmaceutical through a combination of "share transfer and private placement," with a total transaction value of approximately 1.007 billion yuan [3][12]. - The current controlling shareholder, Tai Rong Investment, will transfer 50.1 million shares (8.73% of total shares) at a price of 11.043 yuan per share, with the total payment for the share transfer being approximately 553 million yuan [3][12]. - Jiang Pharmaceutical Holdings plans to subscribe to approximately 74.6 million shares at a price of 6.09 yuan per share, raising up to 454 million yuan [3][12]. Group 2: Financial Performance - Jiang Pharmaceutical Holdings, established on May 7, 2025, is a wholly-owned subsidiary of Jiang Pharmaceutical Group, focusing on the outpatient market, including single pharmacies and clinics [4][14]. - The revenue and net profit of Jiang Pharmaceutical Group have shown steady growth over the past four years, with revenues of 6.736 billion yuan, 12.137 billion yuan, 12.731 billion yuan, and 9.385 billion yuan from 2022 to September 2025, and net profits of 15.7097 million yuan, 58.4096 million yuan, 73.6069 million yuan, and 50.3908 million yuan during the same period [4][14]. Group 3: Market Insights - Tai Long Pharmaceutical's traditional Chinese medicine oral preparations cover key areas such as respiratory, digestive, and cardiovascular diseases, with traditional Chinese medicine sales accounting for 37% of the urban pharmacy market in China [5][16]. - In online pharmacies, traditional Chinese medicine market share is slightly lower at around 30%, with the top three categories being urological, digestive, and respiratory disease medications [5][17]. - The performance of cardiovascular disease medications in grassroots medical institutions is particularly strong, with market shares exceeding 30% [5][17]. Group 4: Industry Trends - The acquisition of Tai Long Pharmaceutical by Jiang Pharmaceutical Holdings reflects a growing trend of state-owned enterprises acquiring pharmaceutical companies, supported by policies such as the "merger and acquisition guidelines" [7][19]. - Other recent acquisitions in the pharmaceutical sector include various state-owned enterprises enhancing their capital strength and resource acquisition through direct share purchases and indirect control arrangements [8][20].